Breaking News

Tweet TWEET

R&D Milestones, Response on Published Reports, and Independent Clinical Programs Widen Growth Opportunities for Biotech

   R&D Milestones, Response on Published Reports, and Independent Clinical
Programs Widen Growth Opportunities for Biotech Companies - Research Report on
                Verastem, Acorda, Hyperion, XOMA, and Lexicon

PR Newswire

NEW YORK, July 3, 2013

NEW YORK, July 3, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Wall Street Reports announced new research reports highlighting
Verastem, Inc. (NASDAQ: VSTM), Acorda Therapeutics (NASDAQ: ACOR), Hyperion
Therapeutics, Inc. (NASDAQ: HPTX), XOMA Corporation (NASDAQ: XOMA), and
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Verastem, Inc. Research Report

On June 27, 2013, Verastem, Inc. (Verastem) announced that it has successfully
completed the Phase I stage of combination trial of VS-6063 and paclitaxel.
Manish Patel, M.D., Principal Investigator, Florida Cancer Specialists, said,
"The combination of VS-6063 and weekly paclitaxel has been well tolerated,
with no unexpected toxicity, and no worsening of the well understood side
effects of paclitaxel." Patel continued, "The observation that 3 of the 4
patients continuing on study have had a significant reduction in the CA-125
level is encouraging." Robert Forrester, President and Chief Operating Officer
of Verastem, stated, "With the completion of the dose escalation stage, we are
now initiating an expansion cohort of patients with ovarian cancer to further
evaluate the activity of the combination therapy. Importantly, the ability to
combine VS-6063 with paclitaxel provides an opportunity to explore multiple
additional indications where the tumors are driven by cancer stem cells and
paclitaxel is the standard of care." The Full Research Report on Verastem,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.WSReports.com/r/full_research_report/cbde_VSTM]

--

Acorda Therapeutics, Inc. Research Report

On June 26, 2013, Acorda Therapeutics, Inc. (Acorda) announced the results of
its first clinical study to assess pharmacokinetics, safety and tolerability
of Diazepam Nasal Spray in people with epilepsy. According to the Company, the
Diazepam Nasal Spray is being developed for the treatment of people with
epilepsy who experience cluster seizures or acute repetitive seizures. Enrique
Carrazana, M.D., Chief Medical Officer of Acorda, stated, "The study results
showed that the Diazepam Nasal Spray pharmacokinetics are comparable whether
it is administered during or immediately following a seizure. For people with
epilepsy who experience cluster seizures, it is critical that treatment be
administered as soon as a cluster is recognized, to prevent additional seizure
activity." Carrazana added, "Diazepam Nasal Spray offers a therapeutic
alternative that can be administered rapidly and conveniently." The Full
Research Report on Acorda Therapeutics, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.WSReports.com/r/full_research_report/de76_ACOR]

--

Hyperion Therapeutics, Inc. Research Report

On June 18, 2013, Hyperion Therapeutics, Inc. (Hyperion) announced that the
population pharmacokinetic (PK) modeling and dosing simulations based on the
data from its Phase II and III trials were included in The Journal of Clinical
Pharmacology. The Phase II and III trials collectively enrolled patients with
urea cycle disorders (UCDs) of ages 2 months to 72 years. Bruce Scharschmidt,
MD, Chief Medical Officer of Hyperion, stated, "This work represents an
outstanding example of how population PK modeling and dosing simulations can
be used to help understand the behavior of drugs for patients with rare
diseases in which large trials are not feasible. We are pleased to provide the
UCD community with options to treat this serious disease. Specifically, with
our launch of RAVICTI earlier this year, patients now have access to an
important new option." The Full Research Report on Hyperion Therapeutics, Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.WSReports.com/r/full_research_report/5225_HPTX]

--

XOMA Corporation Research Report

On June 25, 2013, XOMA Corporation (XOMA) announced that SERVIER, its
development partner, has launched its own independent Proof-of-Concept (POC)
clinical program to evaluate the safety and efficacy of gevokizumab. XOMA
stated that it had launched a similar POC clinical program in November 2011,
which included studies in three separate indications, including moderate to
severe inflammatory acne vulgaris, erosive inflammatory osteoarthritis of the
hand, and non-anterior scleritis. The Company reported that SERVIER has
selected several indications across multiple therapeutic areas. "We are
impressed with the breadth and depth of SERVIER's development plan. The first
indication they are studying is polymyositis/dermatomyositis. Once SERVIER's
POC program is fully underway, we anticipate gevokizumab will be undergoing
safety and efficacy evaluations in over a dozen potential indications between
SERVIER's and our efforts," commented John Varian, CEO of XOMA. The Full
Research Report on XOMA Corporation - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.WSReports.com/r/full_research_report/9e50_XOMA]

--

Lexicon Pharmaceuticals, Inc. Research Report

On June 24, 2013, Lexicon Pharmaceuticals, Inc. (Lexicon) announced that it
presented the first publication of data on LX2761 during the 73rd Scientific
Sessions of the American Diabetes Association (ADA). Alan Main, Ph.D.,
Executive Vice President of Pharmaceutical Research at Lexicon, said, "LX2761
was designed to act locally in the gastrointestinal tract to reduce glucose
absorption by inhibiting SGLT1 without any significant inhibition of SGLT2 in
the kidney." Main continued, "This was accomplished through a dedicated
medicinal chemistry effort to identify molecules with limited systemic
exposure that showed efficacy in animal models of diabetes." Brian Zambrowicz,
Ph.D., Executive Vice President and Chief Scientific Officer at Lexicon,
commented, "We hope LX2761 may one day treat a large population of patients
with diabetes, and potentially prediabetes, that may wish to avoid the urinary
glucose excretion associated with SGLT2 inhibition in the kidney." Zambrowicz
added, "In addition, the synergy demonstrated with a DPP-4 inhibitor provides
the mechanistic rationale to consider future combination therapies." The Full
Research Report on Lexicon Pharmaceuticals, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.WSReports.com/r/full_research_report/b93b_LXRX]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)